Bristol-Myers Squibb Company Ce's goodwill is $22B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest goodwill for CELG-RI is $22B as of September 2026. That compares with $22B in the prior-year period — up 0.0% year over year. Investors often review this figure alongside Bristol-Myers Squibb Company Ce's historical trend and sector peers before judging valuation or financial health.
Over the past year, CELG-RI's goodwill moved from $22B to $22B — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company Ce's operating scale or balance-sheet position.
A goodwill figure of $22B for CELG-RI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting CELG-RI's goodwill ($22B), review year-over-year change from $22B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.